SAR 445399
Alternative Names: Anti-IL1R3 mAb - Sanofi; MAB-212; SAR-445399Latest Information Update: 15 Jan 2024
At a glance
- Originator MAB Discovery; Sanofi
- Developer Sanofi
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Interleukin-1 receptor accessory protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation